Physician profile
Miranda E Cox
NPI 1417577081
$3,790.56
in general payments reported to CMS, 2019-2025
27 companies · $2,410 in 2025
The $2,410 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $80.01 · 2024: $1,300 · 2025: $2,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,725 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,724.57 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.02 | 2024-2025 | |
| Amgen INC. | $369.80 | 2024-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $367.26 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $327.34 | 2024-2025 | |
| Novo Nordisk INC | $302.15 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $266.09 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $221.96 | 2024-2025 | |
| Astellas Pharma US INC | $177.81 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $160.90 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.00 | 2024 | Ofev, Jardiance, Synjardy |
| Medtronic, INC. | $140.78 | 2025 | Inceptiv |
| Daiichi Sankyo INC. | $105.74 | 2024-2025 | Injectafer |
| Lilly USA, LLC | $97.70 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $94.39 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $90.76 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $82.47 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.79 | 2024-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $38.32 | 2025 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $33.85 | 2024-2025 | Heplisav-B |
| Csl Behring | $27.59 | 2025 | Andembry |
| Phathom Pharmaceuticals, INC. | $27.59 | 2025 | Voquezna |
| Lundbeck LLC | $21.30 | 2025 | Rexulti |
| Dexcom, INC. | $20.86 | 2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $19.34 | 2024 | (Ck7) Extended Holter |
| Merck Sharp & Dohme LLC | $18.78 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Boston Scientific Corporation | $15.46 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $13.51 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.